Evidence map›Paper›PMID 35613850›Full record

ArticleJournal of diabetes2022

Follow-up frequency and clinical outcomes in patients with type 2 diabetes: A prospective analysis based on multicenter real-world data.

Qiubo Zhao, Hongwei Li, Qicheng Ni, Yuancheng Dai, Qidong Zheng, Yufan Wang, Tingyu Ke, Li Li, Dong Zhao, Qijuan Dong and 6 more

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in Journal of diabetes, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 8 institutions in 1 country.

Qiubo ZhaoDepartment of Endocrinology and Metabolism, Hebi Coal (group) Ltd, General Hospital, Hebi, China.
Hongwei LiDepartment of Endocrinology and Metabolism, Hebi Coal (group) Ltd, General Hospital, Hebi, China.
Qicheng NiDepartment of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yuancheng DaiDepartment of Internal Medicine of Traditional Chinese Medicine, Sheyang Diabetes Hospital, Yancheng, China.
Qidong ZhengDepartment of Internal Medicine, The Second People's Hospital of Yuhuan, Yuhuan, China.
Yufan WangDepartment of Endocrinology and Metabolism, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Tingyu KeDepartment of Endocrinology, The Second Affiliated Hospital of Kunming Medical University, Kunming, China.
Li LiDepartment of Endocrinology, Ningbo First Hospital, China.
Dong ZhaoCenter for Endocrine Metabolism and Immune Diseases, Beijing Luhe Hospital, Capital Medical University, Beijing, China.ORCID https://orcid.org/0000-0002-9847-5439
Qijuan DongDepartment of Endocrinology and Metabolism, People's Hospital of Zhengzhou Affiliated Henan University of Chinese Medicine, Zhengzhou, China.
Bangqun JiDepartment of Endocrinology, Xingyi People's Hospital, Xingyi, China.
Juan ShiDepartment of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID https://orcid.org/0000-0003-2652-8084
Ying PengDepartment of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID https://orcid.org/0000-0003-1069-7000
Yifei ZhangDepartment of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID https://orcid.org/0000-0003-0272-0602
Fengmei XuDepartment of Endocrinology and Metabolism, Hebi Coal (group) Ltd, General Hospital, Hebi, China.
Weiqing WangDepartment of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Shanghai Jiao Tong University · CNHefei Design and Research Institute of Coal Industry (China) · CNAnyang Hospital of Traditional Chinese Medicine · CNBeijing Luhe Hospital Affiliated to Capital Medical University · CNFirst Affiliated Hospital of Henan University · CNKunming Medical University · CNNingbo First Hospital · CNYuxian People's Hospital · CN

Funding

Capacity building for multidisciplinary cooperation in diagnosis and treatment of major metabolic diseases No. Z155080000004Chinese Academy of Engineering 2019-XZ-42National Key Research and Development Program of China 2016YFC0901200National Key Research and Development Program of China 2018YFC1311800National Natural Science Foundation of China 82100835Program for Shanghai Outstanding Medical Academic Leader 2019LJ07Shanghai Medical and Health Development Foundation DMRFP_II_01Shanghai Sailing Program 21YF1426900
6 · The paper itself

Abstract

backgroundTo determine whether the follow-up frequency for type 2 diabetes mellitus (T2DM) patients in the National Metabolic Management Centers (MMCs) leads to different clinical outcomes.

methodsA total of 19 908 T2DM patients with at least 6 months of facility-based follow-up were recruited in MMCs between June 2017 and April 2021 and divided into lower-frequency and higher-frequency follow-up (LFF and HFF) groups according to the median follow-up frequency of 2.0 (interquartile range 1.2) times per year. Metabolic parameters at baseline and at the last follow-up visit were analyzed. Multivariable linear regression models were performed to assess the relationship between follow-up frequency and between-group percentage changes, adjusting for the major covariables. Additional stratified analyses were conducted to evaluate the metabolic outcomes in the subgroups.

resultsThe characteristics of the participants in the LFF and HFF groups were significantly different at baseline. Participants had significant improvements in multiple metabolic parameters after follow-up. Patients with HFF showed significantly greater decrease in percentage changes of fasting blood glucose (-4.95% ± 37.96% vs -2.21% ± 43.08%, P < .0001) and glycosylated hemoglobin (HbA1c) (-12.14% ± 19.78% vs -9.67% ± 20.29%, P < .0001) after adjustments compared to those with LFF. Furthermore, stratification analyses showed that significant between-group percentage changes of HbA1c were observed in those with younger age (<55 years) and higher HbA1c (>9%) at baseline (P for interaction <.001).

conclusionsHFF is associated with better metabolic outcomes. Participants, especially with younger age or worse HbA1c at baseline in the HFF group achieved better glycemic control than those in the LFF group.

Indexed as

Diabetes Mellitus, Type 2Blood GlucoseFollow-Up StudiesGlycated HemoglobinGlycemic ControlHumansMiddle AgedBlood GlucoseGlycated Hemoglobin2型糖尿病cost-effectivenessfollow-up frequencyglycemic controltype 2 diabetes mellitus成本效益血糖控制随访频率

Identifiers

PMID35613850
PMCPMC9366569
OpenAlexW4281562495

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.